03-11 07:37 ET - News Release
Mr. Marc Wayne reports
BEDROCAN INITIATES DOMESTIC PRODUCTION OPERATIONS
Bedrocan Cannabis Corp.'s recently licensed domestic production facility in the Greater Toronto Area is now operational. Live plant material consisting of genetic clones of Bedrocan's proprietary strains of medicinal cannabis, has been successfully imported from the Company's Dutch partner Bedrocan BV, and is now growing in the new facility's specially-designed grow rooms.
Bedrocan was issued separate import permits from both Health Canada and the Canadian Food Inspection Agency, allowing for the first-ever legal importation of live cannabis plants into Canada. The use of genetically-identical clones is a critical element of Bedrocan's pioneering standardization process. This process, which also includes a series of unique, proprietary production techniques, results in medicinal cannabis that provides patients with consistent levels of active ingredients (cannabinoids) in every batch, as is required for both prescription and over-the-counter (OTC) medicines. Bedrocan is the only company in the world capable of producing standardized full-bud medicinal cannabis and its alternate dispensed form, "Gran Flos", granulated full bud cannabis.
"We've achieved a major milestone with the launch of domestic production, and the transition to Phase II of our growth strategy," said Marc Wayne, President and CEO of Bedrocan. "The importation process went smoothly, our production technology is working flawlessly, and we're on track to harvest our first domestic crop for shipment to patients in Q2 2015."